Belleville, MI, United States of America

Greg Conley

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Greg Conley - Innovator in the Evaluation and Treatment of pKal-Mediated Disorders.

Introduction

Greg Conley is an accomplished inventor based in the United States. He has made significant contributions to the field of medical research, particularly in the evaluation and treatment of disorders mediated by plasma kallikrein (pKal). His innovative methods aim to improve the diagnosis and management of patients suffering from these conditions.

Latest Patents

Greg Conley holds a patent titled "Evaluation And Treatment Of pKal-Mediated Disorders." This patent outlines methods for evaluating subjects at risk for or suffering from pKal-mediated or bradykinin-mediated disorders. The methods are based on analyzing values of intact and/or cleaved kininogen in a sample from the subject. These techniques are particularly useful for assessing patients with plasma kallikrein-mediated angioedema (KMA) and other related diseases.

Career Highlights

Throughout his career, Greg Conley has focused on developing innovative solutions for complex medical issues. His work has been instrumental in advancing the understanding of pKal-mediated disorders and their treatment. Despite having 1 patents, his contributions to the field are noteworthy and impactful.

Collaborations

Greg has collaborated with notable colleagues, including Daniel J Sexton and Ryan Faucette. These partnerships have enhanced the research and development of methods for evaluating and treating pKal-mediated disorders.

Conclusion

In summary, Greg Conley is a dedicated inventor whose work in the evaluation and treatment of pKal-mediated disorders has the potential to significantly improve patient outcomes. His innovative approaches and collaborations reflect his commitment to advancing medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…